Literature DB >> 12871882

Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours.

Emile Daraï1, Romain Detchev, Danielle Hugol, Nhuan Tran Quang.   

Abstract

BACKGROUND: Altered expression of cytokines has been suggested as a specific event for the maintenance and progression of endometriomas. Few data exist on cytokine expression in endometriomas compared with benign and malignant ovarian tumours. Hence, serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor-alpha (TNF-alpha) were evaluated in women with endometriomas and compared with those in women with benign or malignant ovarian tumours.
METHODS: Investigations included immunoradiometric determination of serum and cyst fluid concentrations of IL-6, IL-8 and TNF-alpha in 34 women with endometriomas, 30 women with benign and 13 women with malignant cystic ovarian tumours.
RESULTS: Serum IL-6 levels were higher in ovarian cancer than in endometriomas (P<0.01) or benign tumours (P<0.01). Serum TNF-alpha levels differed between benign tumours and endometriomas (P<0.01), but not between endometriomas and malignant tumours. Cyst fluid levels of IL-8 were higher in endometriomas than in benign tumours (P<0.001) and lower than in malignant tumours (P=0.03). Cyst fluid levels of TNF-alpha differed between malignant tumours and endometriomas (P<0.01) and benign tumours (P<0.01), but not between endometriomas and benign tumours. In the endometriomas group, a positive correlation was found between serum and cyst fluid levels of IL-6 (P=0.003, rho=0.633), and between serum levels of IL-6 and IL-8 (P=0.03, rho=0.415).
CONCLUSIONS: Endometriomas were associated with serum TNF-alpha levels similar to those found in women with ovarian cancer, while serum IL-6 levels and cyst fluid IL-8 levels were intermediate between those observed in benign and malignant ovarian tumours.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871882     DOI: 10.1093/humrep/deg321

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  28 in total

Review 1.  Peripheral biomarkers of endometriosis: a systematic review.

Authors:  K E May; S A Conduit-Hulbert; J Villar; S Kirtley; S H Kennedy; C M Becker
Journal:  Hum Reprod Update       Date:  2010-05-12       Impact factor: 15.610

Review 2.  Immunologic factors involved in the malignant transformation of endometriosis to endometriosis-associated ovarian carcinoma.

Authors:  S Leenen; M Hermens; P J de Vos van Steenwijk; R L M Bekkers; E M G van Esch
Journal:  Cancer Immunol Immunother       Date:  2021-01-07       Impact factor: 6.968

3.  Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update.

Authors:  Subeka Abraham Gnanadass; Yogamaya Divakar Prabhu; Abilash Valsala Gopalakrishnan
Journal:  Arch Gynecol Obstet       Date:  2021-01-13       Impact factor: 2.344

4.  Association of the neutrophil-to-lymphocyte ratio and CA 125 with the endometriosis score.

Authors:  Seul Ki Kim; Jung Yeon Park; Byung Chul Jee; Chang Suk Suh; Seok Hyun Kim
Journal:  Clin Exp Reprod Med       Date:  2014-12-31

Review 5.  Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects.

Authors:  Jian-Jun Wei; Josette William; Serdar Bulun
Journal:  Int J Gynecol Pathol       Date:  2011-11       Impact factor: 2.762

Review 6.  TNF-alpha and its inhibitors in cancer.

Authors:  Inès Zidi; Souhir Mestiri; Aghleb Bartegi; Nidhal Ben Amor
Journal:  Med Oncol       Date:  2009-03-11       Impact factor: 3.064

Review 7.  Blood biomarkers for the non-invasive diagnosis of endometriosis.

Authors:  Vicki Nisenblat; Patrick M M Bossuyt; Rabia Shaikh; Cindy Farquhar; Vanessa Jordan; Carola S Scheffers; Ben Willem J Mol; Neil Johnson; M Louise Hull
Journal:  Cochrane Database Syst Rev       Date:  2016-05-01

8.  TNF-α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis?

Authors:  Mamta Gupta; Ana Babic; Andrew H Beck; Kathryn Terry
Journal:  Hum Pathol       Date:  2016-04-08       Impact factor: 3.466

9.  A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor α receptor 2 levels and risk of ovarian cancer.

Authors:  Elizabeth M Poole; I-Min Lee; Paul M Ridker; Julie E Buring; Susan E Hankinson; Shelley S Tworoger
Journal:  Am J Epidemiol       Date:  2013-08-21       Impact factor: 4.897

10.  Phase II biomarker trial of a multimarker diagnostic for ovarian cancer.

Authors:  Tracey Edgell; G Martin-Roussety; G Barker; D J Autelitano; D Allen; P Grant; G E Rice
Journal:  J Cancer Res Clin Oncol       Date:  2010-01-16       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.